Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Benitec Biopharma (BNTC) Equity Ratio (2019 - 2025)

Benitec Biopharma's Equity Ratio history spans 5 years, with the latest figure at 0.96 for Q4 2024.

  • For Q4 2024, Equity Ratio rose 32.57% year-over-year to 0.96; the TTM value through Dec 2024 reached 0.96, up 32.57%, while the annual FY2024 figure was 0.9, 1899.87% up from the prior year.
  • Equity Ratio for Q4 2024 was 0.96 at Benitec Biopharma, up from 0.9 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.96 in Q4 2024 and bottomed at 0.05 in Q2 2023.
  • The 5-year median for Equity Ratio is 0.82 (2023), against an average of 0.77.
  • The largest annual shift saw Equity Ratio crashed 90.62% in 2023 before it surged 1899.87% in 2024.
  • A 5-year view of Equity Ratio shows it stood at 0.94 in 2020, then dropped by 17.99% to 0.77 in 2021, then rose by 4.33% to 0.81 in 2022, then dropped by 10.19% to 0.72 in 2023, then skyrocketed by 32.57% to 0.96 in 2024.
  • Per Business Quant, the three most recent readings for BNTC's Equity Ratio are 0.96 (Q4 2024), 0.9 (Q2 2024), and 0.72 (Q4 2023).